ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy

被引：0
|
作者：
Evans, T. R. Jeffry
Kudo, Masatoshi
Cheng, Ann-Lii
Wyrwicz, Lucjan S.
Ngan, Roger Kc
Blanc, Jean-Frederic
Baron, Ari David
Vogel, Arndt
Ikeda, Masafumi
Piscaglia, Fabio
Qin, Shukui
Hoshi, Taisuke
Tamaki, Ryuji
Funahashi, Yasuhiro
Okpara, Chinyere E.
Sagane, Koji
Xing, Dongyuan
Minoshima, Yukinori
Finn, Richard S.
机构：
[1] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[6] Univ Hong Kong, Hong Kong, Peoples R China
[7] Univ Bordeaux, Bordeaux, France
[8] Sutter Calif Pacif Med Ctr, San Francisco, CA USA
[9] Hannover Med Sch, Hannover, Germany
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy
[12] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[13] Eisai & Co Ltd, Ibaraki, Japan
[14] Eisai Ltd, Hatfield, Herts, England
[15] Eisai Inc, Nutley, NJ USA
[16] UCLA Med Ctr, Geffen Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4094
引用
收藏
页数：1
相关论文
共 50 条
  • [41] SECOND INTERIM ANALYSIS OF GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN UNRESECTABLE HEPATOCELLULAR CARCINOMA [UHCC] AND OF ITS TREATMENT WITH SORAFENIB): SUBGROUP ANALYSIS BY INITIAL SORAFENIB (SOR) DOSE
    Marrero, Jorge A.
    Venook, Alan
    Kudo, Masatoshi
    Ye, Sheng-Long
    Nakajima, Keiko
    Cihon, Frank
    Lencioni, Riccardo
    HEPATOLOGY, 2011, 54 : 1389A - 1389A
  • [42] Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation
    Park, Min Kyung
    Lee, Yun Bin
    Moon, Hyemi
    Choi, Na Ryung
    Kim, Minseok Albert
    Jang, Heejoon
    Nam, Joon Yeul
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (10) : 4939 - 4949
  • [43] Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
    Chen, Yen-Yang
    Wang, Chih-Chi
    Liu, Yueh-Wei
    Li, Wei-Feng
    Chen, Yen-Hao
    PEERJ, 2020, 8
  • [44] EFFECTIVENESS OF LENVATINIB VERSUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATIC DECOMPENSATION
    Park, Min Kyung
    Lee, Yun Bin
    Moon, Hyemi
    Choi, Na Ryung
    Kim, Minseok Albert
    Nam, Joon Yeul
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    HEPATOLOGY, 2021, 74 : 637A - 637A
  • [45] Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation
    Min Kyung Park
    Yun Bin Lee
    Hyemi Moon
    Na Ryung Choi
    Minseok Albert Kim
    Heejoon Jang
    Joon Yeul Nam
    Eun Ju Cho
    Jeong-Hoon Lee
    Su Jong Yu
    Yoon Jun Kim
    Jung-Hwan Yoon
    Digestive Diseases and Sciences, 2022, 67 : 4939 - 4949
  • [46] Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Zheng, Bin
    Liu, Maobai
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (08) : 553 - 562
  • [47] Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
    Sekiguchi, Shuhei
    Tsuchiya, Kaoru
    Yasui, Yutaka
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Hayakawa, Yuka
    Osawa, Leona
    Higuchi, Mayu
    Takaura, Kenta
    Maeyashiki, Chiaki
    Kaneko, Shun
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Kurosaki, Masayuki
    Izumi, Namiki
    CANCER REPORTS, 2022, 5 (11)
  • [48] Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).
    Tran, Nguyen H.
    Soefje, Scott A.
    Rangarajan, Nivedita
    Purushotham, K.
    Nadig, Mihika
    Wagner, Tyler E.
    Valerio, Stephen J.
    Anderson, Rye
    Olson, Jody C.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 572 - 572
  • [49] Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis
    Qin, S.
    Guo, Y.
    Meng, Z.
    Wu, J.
    Gu, K.
    Zhang, T.
    Lin, X.
    Lin, H.
    Ying, J-E.
    Zhou, F.
    Hsing-Tao, K.
    Chao, Y.
    Li, S.
    Chen, Y.
    Boisserie, F.
    Abdrashitov, R.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1454 - S1455
  • [50] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
12345